Patents Examined by Sarah Pihonak
  • Liquid tasimelteon formulations and methods of use thereof
    Patent number: 11202770
    Abstract: Liquid suspensions of tasimelteon and methods for their use.
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: December 21, 2021
    Assignee: VANDA PHARMACEUTICALS INC.
    Inventors: Deepak Phadke, Mihael Polymeropoulos
  • Curcuphenol compounds for increasing MHC-I expression
    Patent number: 11197832
    Abstract: Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.
    Type: Grant
    Filed: August 20, 2020
    Date of Patent: December 14, 2021
    Assignee: Cava Healthcare Inc.
    Inventors: Wilfred Jefferies, Reinhard Gabathuler, Raymond Andersen, Lilian Nohara, David Williams
  • Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis
    Patent number: 11197864
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole pro drugs useful for the treatment of amyotrophic lateral sclerosis (ALS) and related disorders through the release of riluzole, especially to avoid patient to patient variability in first pass, hepatic metabolism promoted by Cyp 1?2. Pro-drugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process. The invention further includes pro-drugs of riluzole useful for the treatment of disease states that can be treated with riluzole through the release of riluzole from a pro-drug agent.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: December 14, 2021
    Assignee: Biohaven Pharmaceutical Holding Company Limited
    Inventors: Allen B. Reitz, Garry Robert Smith
  • Combination of pimavanserin and cytochrome P450 modulators
    Patent number: 11191757
    Abstract: A method for treating a disease or disorder in a patient who is currently taking a cytochrome P450 inhibitor comprising administering to the patient a dose of pimavanserin or a pharmaceutical acceptable salt thereof, wherein the dose is at least 20% lower than a dose of pimavanserin or a pharmaceutical acceptable salt thereof that would otherwise have been recommended to the patient if the patient were not currently taking the cytochrome P450 inhibitor.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: December 7, 2021
    Assignee: ACADIA Pharmaceuticals Inc.
    Inventor: Andrew Parkinson
  • Arginine silicate for periodontal disease
    Patent number: 11191735
    Abstract: Methods for treating and/or preventing periodontal disease with arginine silicate are disclosed. Methods may include the steps of identifying an individual in need of treatment for, or in need of prevention of, periodontal disease and administering an effective amount of an arginine-silicate complex to said individual. Arginine silicate may also be used to ameliorate one or more symptoms of periodontal disease. In some aspects, arginine silicate may be used to restore gum health and/or stop or reverse recession of the gums and/or the loss of gum tissue in the oral cavity.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: December 7, 2021
    Assignee: NUTRITION 21, LLC
    Inventors: James R Komorowski, Kazim Sahin
  • Peripherally-restricted dual-acting kappa and delta opioid agonist for analgesia in pain states involving the inflammatory response
    Patent number: 11185551
    Abstract: The present disclosure teaches the use of a dual-acting opioid agonist for the treatment of pain (e.g., inflammatory pain). The opioid agonist activates both the kappa and delta opioid receptors to provide synergistic reduction in pain. The opioid agonist is peripherally restricted and does not cross the blood-brain barrier.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: November 30, 2021
    Assignee: Caventure Drug Discovery, Inc.
    Inventor: Craig Hartrick
  • Methods of treating or preventing preterm labor
    Patent number: 11179393
    Abstract: Described herein are methods for treating preterm labor, stopping labor prior to Cesarean delivery, preventing preterm labor, or controlling the timing of parturition by administering a chemical compound, such as a muscarinic receptor antagonist preferably a M, receptor antagonist, or a ?-3 adrenergic agonist. Also described are methods for treating preterm labor, stopping labor preparatory to Cesarean delivers', preventing preterm labor, or controlling the timing of parturition by administering an effective amount of transdermal stimulation, posterior tibial nerve stimulation or another form of non-invasive or invasive neuromodulation, unstimulated or stimulated acupuncture, magnetic field therapy, or vibratory stimulation. These methods may be practiced individually, in combination with each other, or in combination with known tocolytic methods or medications.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: November 23, 2021
    Inventor: Anthony G. Visco
  • Methods of synthesizing pyrazine compounds
    Patent number: 11168086
    Abstract: The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R4 are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: November 9, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Taishan Hu, Xingchun Han, Buyu Kou, Hong Shen, Shixiang Yan, Zhisen Zhang
  • Combinations of PDE1 inhibitors and NEP inhibitors
    Patent number: 11166956
    Abstract: The invention relates to the combination of inhibitors of phosphodiesterase 1 (PDE1) and inhibitors of Neprilysin (NEP) useful for the treatment of certain cardiovascular diseases or related disorders, e.g., hypertension, congestive heart disease, and post-myocardial infarction. In another embodiment, the invention relates to the combination of inhibitors of PDE1 and inhibitors of NEP for the treatment of diseases or disorders characterized by disruption of or damage to various cGMP/PKG mediated pathways in the cardiovascular system (e.g., in cardiac tissue or in arterial smooth muscle).
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: November 9, 2021
    Assignee: Intra-Cellular Therapies, Inc.
    Inventors: Lawrence P. Wennogle, Peng Li
  • Amino acid compositions
    Patent number: 11166979
    Abstract: Methods of improving athletic performance in a human, increasing the bioabsorption of the compound in a human, or of increasing the vasodilative characteristics in a human comprise administering to the human compositions and supplement formulations comprising a compound selected from the group consisting of Carnitine, Taurine, and derivative forms thereof; and a Nitrate are disclosed.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: November 9, 2021
    Assignee: ThermoLife International, LLC
    Inventors: Ronald Kramer, Alexander Nikolaidis
  • Therapeutic combinations of a MEK inhibitor and a BTK inhibitor
    Patent number: 11154554
    Abstract: Therapeutic combinations of a MEK inhibitor and a Bruton's tyrosine kinase (BTK) inhibitor are described. In some embodiments, the invention provides pharmaceutical compositions comprising combinations of a MEK inhibitor and a BTK inhibitor and methods of using the pharmaceutical compositions for treating a disease, in particular a cancer.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: October 26, 2021
    Assignee: Acera Pharma B.V.
    Inventors: Wayne Rothbaum, Brian Lannutti, Allard Kaptein
  • HDAC1,2 inhibitors and methods of using the same
    Patent number: 11154551
    Abstract: Disclosed herein are methods for treating a cancer and a method for sensitizing a cancer to a chemotherapeutic agent. Each method administers an agent that selectively inhibits HDAC1 and HDAC2 to a subject in need thereof. Also disclosed herein are methods for determining if a cancer is sensitive to an agent that selectively inhibits HDAC1 and HDAC2 and methods for monitoring the efficacy of a treatment for a cancer that includes administration of an agent that selectively inhibits HDAC1 and HDAC2.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: October 26, 2021
    Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventor: Srividya Bhaskara
  • Amino acid compositions
    Patent number: 11155524
    Abstract: Methods of producing an amino acid nitrate supplement drink suitable for human consumption are provided. The methods comprise providing a solid nitrate salt of an amino acid and adding an amount of water to the solid nitrate salt of the amino acid to produce the amino acid and nitrate drink, wherein the amount of water is sufficient to dissolve the solid nitrate salt of the amino acid. In particular implementations, the solid nitrate salt of an amino acid is selected from the group consisting of: creatine nitrate, arginine nitrate, leucine nitrate, isoleucine nitrate, valine nitrate, cysteine nitrate, glycine nitrate, agmatine nitrate, beta-alanine nitrate, N-acetyl cysteine nitrate, aspartic acid nitrate, lysine nitrate, histidine nitrate, norvaline nitrate, ornithine nitrate, glutamine nitrate, citrulline nitrate, and betaine nitrate.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: October 26, 2021
    Assignee: ThermoLife International, LLC
    Inventors: Ronald Kramer, Alexandros Nikolaidis
  • Antimicrobial drug synthesis and therapeutic compositions
    Patent number: 11135200
    Abstract: This invention relates to the medical use of an antimicrobial agent, racemic Ornidazole, its (R) and (S) enantiomers, or pharmaceutically acceptable salts or esters thereof, and to methods of treatment which involve treating a subject with Ornidazole. The racemic (rac)-ornidazole, its enantiomers, or pharmaceutically acceptable salts or esters thereof, may be used in combination with other actives. The invention also relates to pharmaceutical formulations and compositions comprising (rac)-ornidazole, (R)-ornidazole, (S)-ornidazole, or pharmaceutically acceptable salts or esters thereof, and/or other actives as well as methods to stereoselectively manufacture the enantiomers.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: October 5, 2021
    Inventor: John Malcolm Hall Gregg
  • Methods of treating or preventing Zika virus infection
    Patent number: 11135219
    Abstract: This document relates to methods and materials for treating a mammal having a Zika virus (ZIKV) infection.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: October 5, 2021
    Assignee: NUtech Ventures
    Inventors: Shi-hua Xiang, Nicholas Palermo, Asit K. Pattnaik, Aryamav ' Pattnaik
  • Quinoline amides and methods of using same
    Patent number: 11135213
    Abstract: The present invention provides novel compounds that are quinoline foldamers. Such foldamers stabilize and bind to islet amyloid polypeptide (IAPP). In certain embodiments, the quinoline foldamers of the invention are soluble and cross biological membranes without cellular assistance. The present invention further provides novel method of preventing or treating diabetes in a subject in need thereof by administering to the subject an effective amount of at least one quinoline foldamer of the invention. The present invention further provides novel method of preventing or treating a neurodegenerative disease caused by a misfolded and/or unstructured protein in a subject in need thereof by administering to the subject an effective amount of at least one quinoline foldamer of the invention.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: October 5, 2021
    Assignee: Yale University
    Inventors: Andrew Miranker, Sunil Kumar
  • Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the Human Immunodeficiency Virus
    Patent number: 11136316
    Abstract: The present invention is directed to new bifunctional compounds and methods for treating HIV infections. The bifunctional small molecules, generally referred to as ARM-HI's, function through orthogonal pathways, by inhibiting the gp120-CD4 interaction, and by recruiting anti-DNP antibodies to gp120-expressing cells, thereby preventing cell infection and spread of HIV. It has been shown that ARM-HI's bind to gp120 and gp-120 expressing cells competitively with CD4, thereby decreasing viral infectivity as shown by an MT-2 cell assay, the binding leading to formation of a ternary complex by recruiting anti-DNP antibodies to bind thereto, the antibodies present in the ternary complex promoting the complement-dependent destruction of the gp120-expressing cells. Compounds and methods are described herein.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: October 5, 2021
    Assignee: YALE UNIVERSITY
    Inventors: David Spiegel, Christopher Parker
  • Compositions and methods for inhibiting Dkk-1
    Patent number: 11135223
    Abstract: The present invention provides compositions and methods for inhibiting Dkk-1 for treating or preventing an inflammatory or inflammatory-related disease or disorder.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: October 5, 2021
    Assignee: Yale University
    Inventors: Wook-Jin Chae, Alfred Bothwell
  • Treating of side-effects resulting from chemodenervation
    Patent number: 11129822
    Abstract: The present disclosure relates generally to methods of restoring neuromuscular transmission by locally administering an effective dose of a composition comprising an anticholinesterase to a non-responsive muscle. The disclosure also relates to methods of reversing a neurotoxin-induced muscle paralysis or muscle weakness, the method comprising locally administering a composition comprising an anticholinesterase to the patient.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: September 28, 2021
    Inventor: Mary Gardner
  • Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer
    Patent number: 11129397
    Abstract: The present invention includes methods of stabilizing one or more sweet enhancers when they are exposed to a light source as well as liquid compositions containing one or more sweet enhancers and one or more photostabilizers.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: September 28, 2021
    Assignee: FIREMENICH INCORPORATED
    Inventors: Catherine Tachdjian, Donald Karanewsky, Xiao Qing Tang, Hanghui Liu